TY - JOUR
T1 - Contrast-Induced Nephropathy After Cardiac Catheterization
T2 - Culprits, Consequences and Predictors
AU - Sedhai, Yub Raj
AU - Golamari, Reshma
AU - Timalsina, Santosh
AU - Basnyat, Soney
AU - Koirala, Ajay
AU - Asija, Ankush
AU - Choksi, Tatvam
AU - Kushwah, Akanksha
AU - Geovorgyan, David
AU - Dar, Tawseef
AU - Borikar, Madhura
AU - Ahangar, Waseem
AU - Alukal, Joseph
AU - Zia, Subtain
AU - Missri, Jose
N1 - Publisher Copyright:
© 2017 Southern Society for Clinical Investigation
PY - 2017
Y1 - 2017
N2 - Background Contrast-induced nephropathy (CIN) is a common complication after radiocontrast exposure. Methods A retrospective medical record review of 513 hospitalized patients who underwent cardiac catheterization from June-December 2014 was done, of which 38 patients with end-stage renal disease and 57 patients without preprocedural creatinine were excluded. Serum creatinine concentration before the procedure and each day for 3 days after the procedure was recorded. CIN was defined as an increase in serum creatinine concentration by ≥25% or ≥0.5 mg/dL from the preprocedural value within 72 hours of contrast exposure. Results A total of 418 patients (mean age: 69.1 ± 13.8 years, 55% males) were included in the study. Mean incidence of CIN was 3.7% (n = 16). CIN accounted for longer duration of hospitalization, lengthier intensive care unit admission, requirement of hemodialysis and higher mortality. Incidence of CIN was higher in the presence of preexisting atrial fibrillation (AF), congestive heart failure (CHF) and chronic kidney disease (CKD). When tested by univariate analysis, incidence of CIN was 13.8% in the AF group (P < 0.001), 8.6% in CHF group (P < 0.01) and 8.9% in CKD group (P < 0.002), compared with 2.3%, 1.9% and 2.4% in the absence of preexisting AF, CHF and CKD, respectively. On further testing using multivariate logistic regression model using AF, CHF and CKD as independent variables, development of CIN was strongly associated with preexisting AF with an odds ratio of 4.11, 95% CI: 1.40-12.07, P = 0.01. Conclusion Identifying patients at risk is an important step in preventing CIN. Preexisting AF, independent of traditional risk factors, may increase the risk for CIN.
AB - Background Contrast-induced nephropathy (CIN) is a common complication after radiocontrast exposure. Methods A retrospective medical record review of 513 hospitalized patients who underwent cardiac catheterization from June-December 2014 was done, of which 38 patients with end-stage renal disease and 57 patients without preprocedural creatinine were excluded. Serum creatinine concentration before the procedure and each day for 3 days after the procedure was recorded. CIN was defined as an increase in serum creatinine concentration by ≥25% or ≥0.5 mg/dL from the preprocedural value within 72 hours of contrast exposure. Results A total of 418 patients (mean age: 69.1 ± 13.8 years, 55% males) were included in the study. Mean incidence of CIN was 3.7% (n = 16). CIN accounted for longer duration of hospitalization, lengthier intensive care unit admission, requirement of hemodialysis and higher mortality. Incidence of CIN was higher in the presence of preexisting atrial fibrillation (AF), congestive heart failure (CHF) and chronic kidney disease (CKD). When tested by univariate analysis, incidence of CIN was 13.8% in the AF group (P < 0.001), 8.6% in CHF group (P < 0.01) and 8.9% in CKD group (P < 0.002), compared with 2.3%, 1.9% and 2.4% in the absence of preexisting AF, CHF and CKD, respectively. On further testing using multivariate logistic regression model using AF, CHF and CKD as independent variables, development of CIN was strongly associated with preexisting AF with an odds ratio of 4.11, 95% CI: 1.40-12.07, P = 0.01. Conclusion Identifying patients at risk is an important step in preventing CIN. Preexisting AF, independent of traditional risk factors, may increase the risk for CIN.
UR - http://www.scopus.com/inward/record.url?scp=85030557778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030557778&partnerID=8YFLogxK
U2 - 10.1016/j.amjms.2017.05.010
DO - 10.1016/j.amjms.2017.05.010
M3 - Article
C2 - 29173356
AN - SCOPUS:85030557778
SN - 0002-9629
VL - 354
SP - 462
EP - 466
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 5
ER -